Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs.

Cancers (Basel)

Department of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Building 112, 2160 South First Avenue, Maywood, IL 60153, USA.

Published: November 2020

This review provides an update on the current use of immune checkpoint inhibitors (ICI) in female gynecologic cancers, and it addresses the potential of these agents to provide therapy options for disease management and long-term remission in advanced disease patients, where surgery, chemotherapy, and/or radiation fail to meet this goal. The topic of immune checkpoint inhibitors (ICI) blocking cytotoxic T lymphocyte associated protein-4 (CTLA-4) and the programmed death-1 (PD-1) axis has come to the forefront of translational medicine over the last decade for several malignancies. The text will focus primarily on a discussion of ovarian cancer, which is the most frequent cause of death of gynecologic cancers; endometrial cancer, which is the most often diagnosed gynecologic cancer; and cervical cancer, which is the third most common female gynecologic malignancy, all of which unfavorably alter the lives of many women. We will address the critical factors that regulate the outcome of these cancer types to ICI therapy, the ongoing clinical trials in this area, as well as the adverse immune responses that impact the outcome of patients given ICI regimens.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695253PMC
http://dx.doi.org/10.3390/cancers12113301DOI Listing

Publication Analysis

Top Keywords

immune checkpoint
12
gynecologic cancers
12
checkpoint inhibitors
8
inhibitors ici
8
female gynecologic
8
gynecologic
5
cancer
5
immune
4
checkpoint blockade
4
blockade gynecologic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!